1379 related articles for article (PubMed ID: 26311513)
1. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
2. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Kashiwagi E; Masubuchi D; Eto M; Uchiumi T; Naito S
Oncogene; 2010 Jan; 29(2):237-50. PubMed ID: 19802001
[TBL] [Abstract][Full Text] [Related]
3. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications.
Deng Q; Tang DG
Endocr Relat Cancer; 2015 Dec; 22(6):T209-20. PubMed ID: 26285606
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
7. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
8. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.
Hu J; Tian J; Zhu S; Sun L; Yu J; Tian H; Dong Q; Luo Q; Jiang N; Niu Y; Shang Z
Br J Cancer; 2018 Jan; 118(1):88-97. PubMed ID: 29123266
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
10. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
11. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
13. Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells.
Shiota M; Zardan A; Takeuchi A; Kumano M; Beraldi E; Naito S; Zoubeidi A; Gleave ME
Cancer Res; 2012 Oct; 72(20):5261-72. PubMed ID: 22896337
[TBL] [Abstract][Full Text] [Related]
14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
15. [Prostate cancer and apoptosis].
Mayora A; Arvelo F
Invest Clin; 2011 Dec; 52(4):376-96. PubMed ID: 22523847
[TBL] [Abstract][Full Text] [Related]
16. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
17. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
18. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
19. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study.
Sun A; Tang J; Terranova PF; Zhang X; Thrasher JB; Li B
Int J Cancer; 2010 Feb; 126(3):764-74. PubMed ID: 19642108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
